Advertisement

Lung Transplantation for Interstitial Lung Disease

  • Monique Anne Malouf
Chapter

Abstract

This chapter aims to review the need for lung transplantation for interstitial lung diseases in particular for idiopathic pulmonary fibrosis (IPF), which often fails to respond to medical therapy. The American Thoracic Society recognizes that supplemental oxygen and transplantation are the only suggested treatments for IPF. Prognosis of IPF is generally poor, retrospective cohort studies indicate a median survival of 2–3 years from diagnosis and only 20–30% survive 5 years after diagnosis. Consequently patients with this condition are at increased risk of mortality and lung transplantation offers hope to patients, who are found to be suitable after careful selection for this life saving procedure. Over the past 2–3 decades significant improvements in long term survival and quality of life have been demonstrated. However survival after lung transplantation remains significantly shorter than survival reported in other solid organ transplants (SOT) due to chronic lung allograft dysfunction (CLAD) and infection.

Notes

Acknowledgment

The author is grateful to the anatomical department of St. Vincent’s hospital for graciously providing anatomical histology of the various interstitial lung diseases required for this chapter.

References

  1. 1.
    Leibow AA, Carrington CB. The interstitial pneumonia. In: Simon M, Potchen EJ, LeMay M, editors. Frontiers of pulmonary radiology. 1st ed. New York: Grune & Stratton; 1969. p. 102–41.Google Scholar
  2. 2.
    Travis WD, Costabel U, Hansell DM, et al. American Thoracic Society/European Respiratory Society: international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002;165(2):277–304.CrossRefGoogle Scholar
  3. 3.
    Troy L, Corte T. Interstitial lung disease in 2015: where are we now? Aust Fam Physician. 2015;44(8):546–52.PubMedGoogle Scholar
  4. 4.
    Raghu G, Collard HR. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.  https://doi.org/10.1164/rccm.2009.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Selman M, Pardo A. Idiopathic pulmonary fibrosis: an epithelial fibroblast cross talk disorder. Respir Res. 2002;3:3.CrossRefPubMedGoogle Scholar
  6. 6.
    Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med. 2001;345:517–25.  https://doi.org/10.1056/NEJMra003200.CrossRefPubMedGoogle Scholar
  7. 7.
    Carmelo A, Dunmore R, Sleeman MA, et al. The epithelium in idiopathic pulmonary fibrosis: breaking the barrier. Front Pharmacol. 2014;4:173.Google Scholar
  8. 8.
    Cooper JA Jr, White DA, Matthay RA. Drug induced pulmonary disease. Part 1: cytoxic drugs. Am Rev Respir Dis. 1986;133:321–40.PubMedGoogle Scholar
  9. 9.
    Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline. Thorax. 2008;63(Suppl 5):v1–v58.PubMedGoogle Scholar
  10. 10.
    Raghu C, Mageto YN, Lockhart D, et al. The accuracy of the clinical diagnosis of new onset idiopathic pulmonary fibrosis. Chest. 1999;116:1168–74.CrossRefPubMedGoogle Scholar
  11. 11.
    King TE Jr, Tooze JA, Schwatz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001;164:171–1181.Google Scholar
  12. 12.
    Gribbin J, Hubbard RB, Le Jeune I, et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006;61:908–85.CrossRefGoogle Scholar
  13. 13.
    Flaherty KR, King TE Jr, Raghu G, et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med. 2004;170:904–10.CrossRefPubMedGoogle Scholar
  14. 14.
    Yang S, Raghu G, et al. Clinical evidence in diffuse parenchymal lung disease. Basel: Karger; 2007. p. 22–8.Google Scholar
  15. 15.
    Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34(1):1–15.CrossRefPubMedGoogle Scholar
  16. 16.
    Richeldi L, Costabel U, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079–87.CrossRefPubMedGoogle Scholar
  17. 17.
    Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.CrossRefPubMedGoogle Scholar
  18. 18.
    King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.CrossRefPubMedGoogle Scholar
  19. 19.
    Jo HE. TSANZ position statement: treatment of idiopathic pulmonary fibrosis. Respirology. 2017;22:1436.CrossRefPubMedGoogle Scholar
  20. 20.
    Ragu G. Idiopathic pulmonary fibrosis: a rational approach. Chest. 1987;92:148–54.CrossRefGoogle Scholar
  21. 21.
    Selman M, Carrilo G, Estrada A, et al. Accelerated variance of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One. 2007;2:e48.CrossRefGoogle Scholar
  22. 22.
    Mejia M, Carrilo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and empysema: decreased survival associated with severe PAH. Chest. 2009;136:10–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis:a population- based study. Arthritis Rheum. 2010;62:1583–91.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002;165:1581–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Group TLT: Toronto Lung Transplant Group. Unilateral lung transplantation for pulmonary fibrosis. N Engl J Med. 1986;314(18):1140–5.CrossRefGoogle Scholar
  26. 26.
    Christie JD, Edwards LB, Aurora P, et al. The registry of the International Society for Heart and Lung Transplantation: thirteenth official pediatric lung and heart-lung transplantation report—2010. The official report ISHLT. J Heart Lung Transplant. 2009;28(10):993–1006.CrossRefPubMedGoogle Scholar
  27. 27.
    Yusen RD, Shearon TH, Qian Y, et al. Lung transplantation in USA 1999-2006. Am J Transplant. 2010;10(4 Pt 2):1047–68.CrossRefPubMedGoogle Scholar
  28. 28.
    Timothy JG, Aranaoutakis GJ, et al. Lung transplant in idiopathic pulmonary fibrosis. Arch Surg. 2011;146(10):1204–9.CrossRefGoogle Scholar
  29. 29.
    Armanios M. Telomeres and age relate disease: how telomere biology informs clinical paradigms. J Clin Invest. 2013;123:996–1002.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Silhan LL, Shah PD, Chambers DC, et al. Lung transplantation in telomerase mutation carriers with pulmonary fibrosis. Eur Respir J. 2014;44:178–87.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guidelines: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3–e19.CrossRefPubMedGoogle Scholar
  32. 32.
    ISHLT Registry Report in the JHLT 2017;36(10):1037–79.Google Scholar
  33. 33.
    Kistler K, Nalysnk L, Rotella P, et al. Lung transplantation in idiopathic pulmonary fibrosis: a systemic review of the literature. BMC Pulm Med. 2014;14:139.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Force SD, Kilgo P, Neujahr DC, et al. Bilateral lung transplantation offers better long term survival, compared with single lung transplantation for younger patients with idiopathic pulmonary fibrosis. Ann Thorac Surg. 2011;91:244–9.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Mason DP, Brizzio ME, Alster JM, et al. Lung transplantation for idiopathic pulmonary fibrosis. Ann Thorac Surg. 2007;84:1121–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Neurohr C, Huppmann P, Thum D, et al. Potential functional and survival benefit of double over single lung transplantation for selected patients with idiopathic pulmonary fibrosis. Transpl Int. 2010;23:887–96.PubMedGoogle Scholar
  37. 37.
    De Oliveria NC, Osaki S, Maloney J, et al. Lung transplant for interstitial lung disease: outcomes for single versus bilateral lung transplantation. Interact Cardiovasc Thorac Surg. 2012;14:263–7.CrossRefGoogle Scholar
  38. 38.
    Yusen RD, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-first adult and heart lung transplant report—2014: focus theme: retransplantation. J Heart Lung Transplant. 2014;33(10):1009.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Newton CA, Kozlitina J, Lines JR, et al. Telomere length in patients with pulmonary fibrosis associated with chronic lung allograft and post-lung transplant survival. J Heart Lung Transplant. 2017;36(8):845–53.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Collins J, Kazerooni EA, Lacomis J, et al. Bronchogenic carcinoma after lung transplantation: frequency, clinical characteristics and imaging findings. Radiology. 2002;224:131–18.CrossRefPubMedGoogle Scholar
  41. 41.
    Dickinson RP, Davis RD, Rea JB, et al. High frequency of bronchogenic carcinoma after single lung transplantation. J Heart Lung Transplant. 2006;25:1297–301.CrossRefGoogle Scholar
  42. 42.
    Hubbard RB, Smith C, Le Jeune I. The association between idiopathic pulmonary fibrosis and vascular disease. A population-based study. Am J Respir Crit Care Med. 2008;178:1257–61.  https://doi.org/10.1164/rccm.200805-725OC.CrossRefPubMedGoogle Scholar
  43. 43.
    Kizer JR, Zisman DA, Blumenthal NP, et al. Association between pulmonary fibrosis and coronary artery disease. Arch Intern Med. 2004;164:551–5.CrossRefPubMedGoogle Scholar
  44. 44.
    Lerreri CJ, Nathan SD, Barnett SD, et al. Prevalance and outcomes of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006;129:746–52.CrossRefGoogle Scholar
  45. 45.
    Collard HR, Anstrom KJ, et al. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest. 2009;136:10–5.CrossRefGoogle Scholar
  46. 46.
    Ghofrani HA, Wiedermann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002;360:895–900.CrossRefPubMedGoogle Scholar
  47. 47.
    Ragu G, Behr J, Brown KK, Artemis IPF Investigators*, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomised trial. Ann Intern Med. 2013;148:641–9.CrossRefGoogle Scholar
  48. 48.
    Jackson RM, Glassberg MK, Ramos CF, et al. Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. Lung. 2010;188:115–23.CrossRefPubMedGoogle Scholar
  49. 49.
    Zisman DA, Schartz M, Anstrom KL, Idiopathic Pulmonary Fibrosis Clinical Research Network, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363:620–8.CrossRefPubMedGoogle Scholar
  50. 50.
    Delanote I, Wuyts WA, Yserbyt J, et al. BMC Pulm Med. 2016;16:156.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.The Lung Transplant Unit Xavier Level 4St. Vincent’s HospitalDarlinghurstAustralia

Personalised recommendations